EcoDrugPlus

Sodium Voltage-Gated Channel Alpha Subunit 7

Ensembl ID : ENSMLUG00000009778
Gene Symbol: SCN7A
4 Cross references
86 Possible Orthologues:

Sodium Voltage-Gated Channel Alpha Subunit 8

Ensembl ID : ENSMLUG00000009841
Gene Symbol: SCN8A
2 Cross references
274 Possible Orthologues:

Sodium Voltage-Gated Channel Alpha Subunit 9

Ensembl ID : ENSMLUG00000009695
Gene Symbol: SCN9A
2 Cross references
110 Possible Orthologues:

Sodium-Dependent Serotonin Transporter-Like

Ensembl ID : ENSMLUG00000025630
Gene Symbol: LOC102435223
3 Cross references
202 Possible Orthologues:

Sodium/potassium-Transporting Atpase Subunit Alpha-2-Like

Ensembl ID : ENSMLUG00000001240
Gene Symbol: LOC102417711
3 Cross references
204 Possible Orthologues:

Solute Carrier Family 10 Member 2

Ensembl ID : ENSMLUG00000009360
Gene Symbol: SLC10A2
4 Cross references
214 Possible Orthologues:

Solute Carrier Family 18 Member A2

Ensembl ID : ENSMLUG00000004697
Gene Symbol: SLC18A2
2 Cross references
223 Possible Orthologues:

Solute Carrier Family 29 Member 1 (Augustine Blood Group)

Ensembl ID : ENSMLUG00000005230
Gene Symbol: SLC29A1
2 Cross references
284 Possible Orthologues:

Solute Carrier Family 5 Member 1

Ensembl ID : ENSMLUG00000000838
Gene Symbol: SLC5A1
2 Cross references
250 Possible Orthologues:

Solute Carrier Family 5 Member 2

Ensembl ID : ENSMLUG00000011500
Gene Symbol: SLC5A2
2 Cross references
197 Possible Orthologues:

Solute Carrier Family 6 Member 1

Ensembl ID : ENSMLUG00000002027
Gene Symbol: SLC6A1
2 Cross references
278 Possible Orthologues:

Solute Carrier Family 6 Member 3

Ensembl ID : ENSMLUG00000015691
Gene Symbol: SLC6A3
4 Cross references
166 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects from the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects from the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).